Major Milestones

Eisai in the United States

2016

Eisai Establishes the Eisai Andover Innovative Medicines Institute

BELVIQ XR® (lorcaserin HCl) extended-release tablets approved by FDA

Eisai and Arena Pharmaceuticals granted regulatory approval of VENESPRI® (lorcaserin HCl) in Mexico

Eisai and Novartis enter into collaboration agreement to co-promote LENVIMA® (Lenvatinib) in combination with Everolimus in the U.S.

Eisai relocates North Carolina office to Raleigh from Research Triangle Park

LENVIMA® (lenvatinib) in combination with Everolimus approved by FDA

Fycompa® (perampanel) Oral Suspension approved by FDA. Please see the Fycompa Full Prescribing Information for Boxed WARNING and Additional Important Safety Information

Halaven® (eribulin mesylate) Injection expanded indication approved by the FDA
2015

Eisai and the Paoli Calmettes Institute sign research collaboration agreement

Eisai and Purdue Pharma enter worldwide collaboration to develop and commercialize Lemborexant

Eisai and Halozyme sign collaboration agreement to investigate Eribulin and PEGPH20 in metastatic breast cancer

Eisai Enters Agreement to Transfer Its Research Triangle Park Campus to Biogen

Fycompa® (perampanel) CIII expanded indication approved by the FDA. Please see the Fycompa Full Prescribing Information for Boxed WARNING and Additional Important Safety Information

Banzel® (rufinamide) expanded indication approved by the FDA

LENVIMA® (lenvatinib) receives FDA clearance for marketing

2014

Fycompa® (perampanel) CIII is launched. Please see the Fycompa Full Prescribing Information for Boxed WARNING and Additional Important Safety Information

Eisai enters collaboration with Biogen to develop and commercialize two clinical candidates

Eisai and Merck enter collaboration to explore novel combination regimens

Eisai sells the U.S. rights to Zonegran® (zonisamide) capsules to Concordia Pharmaceuticals Inc., a subsidiary of Concordia Healthcare Corp.

2013

BELVIQ® (lorcaserin HCl) CIV is launched

2012

BELVIQ® (lorcaserin HCl) CIV receives FDA clearance for marketing

Fycompa® (perampanel) CIII receives FDA clearance for marketing. Please see the Fycompa Full Prescribing Information for Boxed WARNING and Additional Important Safety Information.

Eisai establishes strategic manufacturing alliance with Biogen at Eisai’s North Carolina manufacturing facility

Expanding on its original agreement with Arena Pharmaceuticals, Eisai acquires the rights to lorcaserin throughout most of North and South America, including Canada, Mexico and Brazil

2011

Eisai Laboratórios Ltda established in Brazil

Eisai Laboratorios, S de RL de CV established in Mexico

Banzel® (rufinamide) Oral Suspension receives FDA clearance for marketing

2010

Halaven® (eribulin mesylate) Injection receives FDA clearance for marketing

Eisai acquires US rights to lorcaserin from Arena Pharmaceuticals

Eisai Limited established in Canada

H3 Biomedicine Inc. established in Cambridge, Massachusetts

2009

Banzel® (rufinamide) tablets launched

2008

Eisai acquires MGI PHARMA, whose US products include Aloxi® (palonosetron hydrochloride) Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant). The Baltimore, Maryland, manufacturing facility is included in this acquisition  

FDA approves Banzel® (rufinamide) tablets

2007

Eisai Inc. moves to new headquarters in Woodcliff Lake, New Jersey

Eisai acquires Morphotek Inc., a biopharmaceutical company

2006

Eisai Co., Ltd. and Eisai Inc. acquire exclusive rights for four oncology-related products from Ligand Pharmaceuticals

Eisai Inc. breaks ground for a new pharmaceutical production and formulation research and development facility for parenteral oncology treatments at its Research Triangle Park (RTP) campus

2005

Eisai Inc. reaches sales of $2 billion
 

2004

Eisai Inc. gains exclusive U.S. rights to manufacture and market rufinamide, once approved by the U.S. Food and Drug Administration

Eisai Medical Research Inc. establishes new headquarters in Ridgefield Park, New Jersey

Eisai Inc. acquires Zonegran® (zonisamide) capsules from Elan Corporation, obtaining exclusive manufacturing, developing, and marketing rights for the drug in the U.S.

2003

Eisai Inc. assumes U.S. distribution responsibilities for Aricept® (donepezil hydrochloride) tablets

Eisai Inc. expands its Research Triangle Park facility again to increase manufacturing and packaging capabilities; the facility more than doubles in size since its opening in 1997

Eisai Inc. assumes U.S. distribution responsibilities for Aciphex® (rabeprazole sodium) Delayed-Release Tablets

2002

Eisai Inc. reaches sales of $1 billion

Eisai Medical Research Inc. is established to focus solely on clinical research and to expedite clinical drug development of new clinical entities and of new indications for marketed products

2001

Research Triangle Park facility expanded

Production of Aciphex® (rabeprazole sodium) Delayed-Release Tablets begins at Research Triangle Park facility

1999

Aciphex®(rabeprazole sodium) Delayed-Release Tablets receive FDA clearance for marketing

Aciphex® (rabeprazole sodium) Delayed-Release Tablets launched

1998

NDA for Aciphex® (rabeprazole sodium) Delayed-Release Tablets submitted to FDA

Production of Aricept® (donepezil hydrochloride) tablets begins at Research Triangle Park facility

1997 Aricept® (donepezil hydrochloride) tablets launched

Pharmaceutical production and formulation R&D facility established in Research Triangle Park, North Carolina

Agreement forged with Janssen Pharmaceutica Inc. to co-promote Aciphex® (rabeprazole sodium) Delayed-Release Tablets in the United States upon FDA approval
1996 Aricept® (donepezil hydrochloride) tablets receive FDA clearance for marketing

Medical sales force established
1995

Prescription pharmaceutical sales company established as Eisai Inc.

American Depositary Receipt (ADR) established for trading in the over-the-counter market

New Drug Application (NDA) for Aricept® (donepezil hydrochloride) tablets submitted to FDA

1994 Process, research and bulk pharmaceutical company established in Andover, Massachusetts

Agreement forged with Pfizer Inc. to co-promote Aricept® (donepezil hydrochloride) tablets in the United States upon FDA approval
1992 Eisai Corporation of North America established
1987 Eisai Research Institute of Boston established
1981 Eisai U.S.A. established

Eisai Internationally

2016

To learn more about Eisai's global milestones, please click here.